BioSpace News Archive

Growth Driven By the Addition of coflex® Interlaminar Stabilization® Device and Solid Contribution from OEM Franchise

GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc., the world leader in the science, development, and commercialization of cannabinoid prescription medicines, announced that Stephen Schultz, GW’s Vice President of Investor Relations, will present at two upcoming conferences:.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will deliver the following poster presentations at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting to take place November 6-10, 2019 at the Gaylord National Hotel & Convention Center in Baltimore, Maryland:

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced it will host a conference call with management to discuss the third quarter 2019 financial results, provide an update on the company’s business, and discuss expectations for the future on Thursday, November 7, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.

Bristol-Myers Squibb Company reported results for the third quarter of 2019, which were highlighted by strong sales and a robust operating performance, along with the continuing advancement of the company’s pipeline.

Takeda’s 14 global brands with reported revenue of 547.0 billion yen in aggregate posted a strong year-over-year underlying growth of +21%, driven by ENTYVIO growing +33.9%, ALBUMIN/FLEXBUMIN growing +16.9%, and NINLARO growing +32.7%, offset by the negative impact of intensified competition and generic erosion.

Europe has become less competitive than other regions in attracting new ATMP clinical trials.

Cycle Pharmaceuticals Ltd is pleased to announce that it has signed an agreement with Catalent, Inc., to develop innovative formulations targeting rare disease patients.

On Thursday November 14, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q3 2019 interim report The presentation will be held in English..

Positive results from a pooled analysis in highly sensitized patients